1. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD(+) depletion in experimental atrial fibrillation
- Author
-
Zhang, D.L., Hu, X, Li, J. (Juan), Liu, J., Baks-te Bulte, L., Wiersma, M., Malik, N.U., van Marion, DMS, Tolouee, M., Hoogstra-Berends, F. (Femke), Lanters, E.A.H., van Roon, A.M., de Vries, A.A.F., Pijnappels, D.A. (Daniël), Groot, N.M.S. (Natasja) de, Henning, R.H. (Robert), Brundel, B., Zhang, D.L., Hu, X, Li, J. (Juan), Liu, J., Baks-te Bulte, L., Wiersma, M., Malik, N.U., van Marion, DMS, Tolouee, M., Hoogstra-Berends, F. (Femke), Lanters, E.A.H., van Roon, A.M., de Vries, A.A.F., Pijnappels, D.A. (Daniël), Groot, N.M.S. (Natasja) de, Henning, R.H. (Robert), and Brundel, B.
- Abstract
Atrial fibrillation (AF) is the most common clinical tachyarrhythmia with a strong tendency to progress in time. AF progression is driven by derailment of protein homeostasis, which ultimately causes contractile dysfunction of the atria. Here we report that tachypacing-induced functional loss of atrial cardiomyocytes is precipitated by excessive poly(ADP)-ribose polymerase 1 (PARP1) activation in response to oxidative DNA damage. PARP1-mediated synthesis of ADP-ribose chains in turn depletes nicotinamide adenine dinucleotide (NAD+), induces further DNA damage and contractile dysfunction. Accordingly, NAD+ replenishment or PARP1 depletion precludes functional loss. Moreover, inhibition of PARP1 protects against tachypacing-induced NAD+ depletion, oxidative stress, DNA damage and contractile dysfunction in atrial cardiomyocytes and Drosophila. Consistently, cardiomyocytes of persistent AF patients show significant DNA damage, which correlates with PARP1 activity. The findings uncover a mechanism by which tachypacing impairs cardiomyocyte function and implicates PARP1 as a possible therapeutic target that may preserve cardiomyocyte function in clinical AF.
- Published
- 2019
- Full Text
- View/download PDF